Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules.

Biochemistry (Mosc)

Institute of Experimental Cardiology, Russian Cardiology Research Center, Moscow, 121552, Russia.

Published: February 2003

AI Article Synopsis

  • The study focused on the role of glycoprotein IIb-IIIa (GP IIb-IIIa) in platelet secretion from dense and alpha-granules.
  • Monoclonal antibodies that block GP IIb-IIIa activity significantly inhibited serotonin release upon platelet activation, especially with ADP, while showing varying effects with other activators.
  • The findings suggest that the binding of GP IIb-IIIa to fibrinogen is crucial for stimulating granule secretion, but other mechanisms may also be involved, particularly in cases of platelet activation by concanavalin A.

Article Abstract

The involvement of glycoprotein (GP) IIb-IIIa (alphaIIbbeta3-integrin) in the stimulation of secretion from platelet dense and alpha-granules was investigated. Fibrinogen binding with GP IIb-IIIa and platelet aggregation were inhibited by fragments of anti-GP IIb-IIIa monoclonal antibodies (monAB)--Fab fragment of antibody c7E3 (preparation ReoPro) and F(abacute;)(2) fragment of antibody FraMon (preparation FRAMON). Suppression of GP IIb-IIIa receptor activity by both preparations led to 100% inhibition of [(14)C]serotonin secretion from dense granules upon platelet activation with ADP, to partial inhibition upon activation with thromboxane A(2) analog U46619 (by 60-70%) and thrombin at 0.1 U/ml (by 40-50%), but did not decrease serotonin secretion induced by thrombin at 1 U/ml. ReoPro and FRAMON completely inhibited ADP-induced release of soluble P-selectin from platelet alpha-granules, but did not influence P-selectin secretion stimulated by U46619 and by both thrombin concentrations. MonAB CRC54 against GP IIb-IIIa, which induced its interaction with fibrinogen and platelet aggregation, also stimulated serotonin and P-selectin secretion. Both types of release reactions were completely suppressed by ReoPro and FRAMON. Aspirin, the cyclooxygenase inhibitor, also prevented CRC54-induced secretion, proving the dependence of this process on thromboxane A(2) synthesis. Upon platelet activation by concanavalin A (Con A), caused by clusterization of membrane glycoproteins, GP IIb-IIIa blockade only slightly (by 15-20%) decreased serotonin secretion. High level of Con A-induced secretion was also detected in a patient with hereditary deficiency of GP IIb-IIIa. Thus, neither clusterization nor occupation of GP IIb-IIIa are essential for the stimulation of Con A-induced release reaction. The data indicate that GP IIb-IIIa binding with fibrinogen leads to the stimulation of secretion from platelet granules. When the level of secretion does not depend on GP IIb-IIIa interaction with the ligands or its presence on platelets full-scale release reaction is presumably stimulated by activating signals formed without GP IIb-IIIa involvement.

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1022605613859DOI Listing

Publication Analysis

Top Keywords

iib-iiia
12
stimulation secretion
12
secretion platelet
12
secretion
11
glycoprotein iib-iiia
8
platelet
8
platelet granules
8
platelet aggregation
8
fragment antibody
8
platelet activation
8

Similar Publications

Platelet Reactivity to Zika and Dengue Non-Structural Protein 1 (NS1) Assessed by Flow Cytometry, Atomic Force Microscopy, and Quartz Crystal Microbalance.

Int J Lab Hematol

December 2024

División de Estudios de Posgrado. Facultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico.

Background: Platelets, besides being traditionally associated with hemostasis, have been recently positioned as immune cells. Alterations in platelet number and function have been reported in some viral infections. Zika virus (ZIKV) and Dengue virus (DENV) are arboviruses that encode for a non-structural protein 1 (NS1).

View Article and Find Full Text PDF

Platelet-sparing properties of aprotinin: A scoping review on mechanisms and clinical effects.

Eur J Anaesthesiol

January 2025

From the Department of Cardiovascular Sciences, KU Leuven (LLWV, SR, RVdE), and the Department of Anesthesiology, University Hospital of the KU Leuven, Leuven, Belgium (LLWV, SR, RVdE).

Background: Cardiac surgery involving cardiopulmonary bypass (CPB) is associated with the risk of acquired coagulopathy, including dysregulated fibrinolysis, which can result in life-threatening bleeding complications. Aprotinin, an antifibrinolytic agent, has been recommended for the prevention of these complications. Its effectiveness has been attributed to its ability to nonspecifically inhibit various serine proteases involved in the coagulation and fibrinolysis cascade.

View Article and Find Full Text PDF

Gastrointestinal Bleeding/Angiodysplasia in Patients With Glanzmann Thrombasthenia.

J Med Cases

December 2024

Madinah Hereditary Blood Disorders Centre, Department of Hematology and Oncology, King Salman Bin Abdulaziz Medical City, Madinah, Saudi Arabia.

Article Synopsis
  • * A rare complication of GT is gastrointestinal angiodysplasia (GIAD), which involves abnormal blood vessel formation in the digestive system and has been documented in eight cases.
  • * Treatment options for GIAD include surgical methods, electrocoagulation, and medications, but it has a high chance of recurring, as demonstrated in reported cases of patients with both GT and gastrointestinal bleeding.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on identifying risk factors for stent thrombosis (ST) in patients with STEMI who underwent primary PCI, using data from the TOTAL trial involving over 10,000 patients.
  • Out of the participants, 1.54% experienced ST within a year, with factors like prior heart attacks, number of stents, and certain medications influencing risk.
  • The findings suggest that while ST remains a common complication, different predictors exist for ST occurring at different times after the procedure, emphasizing the need for tailored preventive strategies.
View Article and Find Full Text PDF

Background: Intravenous thrombolysis (IVT) is the cornerstone treatment for the acute ischemic stroke (AIS) within 4.5 h after onset. Current guidelines recommend administering antiplatelet medications 24 h after IVT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!